Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase NA 3Phase 4 1

Status

Not yet recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2HR+/HER2- Advanced Breast Cancer 1

Interventions

Exercise 27Standard of Care 24Blood Specimen Collection 18Interviews as Topic 16Educational Status 13Radiosurgery 12Drug Therapy 12Methods 11Surgical Procedures, Operative 10Surveys and Questionnaires 9Saline Solution 9Acupuncture Therapy 9Therapeutics 8Radiotherapy 8Paclitaxel 8Early Intervention, Educational 8Palliative Care 7Magnetic Resonance Spectroscopy 7Electroacupuncture 7Cryotherapy 7Specimen Handling 6Preoperative Exercise 6Practice Guidelines as Topic 6Dexmedetomidine 6Control Groups 6Colonoscopy 6Carboplatin 6tislelizumab 5Resistance Training 5Radiofrequency Ablation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase NA × Not yet recruiting × dalpiciclib × Clear all
NCT06810492 2025-03-17

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

Hubei Cancer Hospital

Phase NA Not yet recruiting
40 enrolled
Breast

Breast Neoplasms

NCT06711094 2024-12-02

Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC

Fujian Medical University

Phase NA Not yet recruiting
52 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

NCT06605690 2024-09-20

An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer

The Affiliated Hospital Of Guizhou Medical University

Phase NA Not yet recruiting
30 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡